NILK-2301 is under clinical development by LamKap Bio Group and currently in Phase I for Metastatic Colorectal Cancer. According to GlobalData, Phase I drugs for Metastatic Colorectal Cancer have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NILK-2301’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NILK-2301 overview

NI-2301 is under development for the treatment of CEA positive solid tumor including metastatic colorectal cancer. It is a bi-specific antibody developed based on kappa-lambda bi-specific antibody platform. They act by targeting CD3.

LamKap Bio Group overview

LamKap Bio Group is a biotechnology company is in the field of research, development, and manufacturing of selected bispecific antibodies for antibody-based therapies of cancer diseases and diseases of the immune system. It is headquartered in Pfaffikon, Zurich, Switzerland.

For a complete picture of NILK-2301’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.